129 related articles for article (PubMed ID: 37062510)
1. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms.
Puzo CJ; Tormey CA; Rinder HM; Siddon AJ
Transplant Cell Ther; 2023 Jul; 29(7):459.e1-459.e4. PubMed ID: 37062510
[TBL] [Abstract][Full Text] [Related]
2. Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation: Comparison of Two Chimerism Test Strategies, Next-Generation Sequencing versus a Combination of Short-Tandem Repeats and Quantitative PCR.
Zhang A; Macecevic S; Thomas D; Allen J; Mandley S; Kawczak P; Jurcago R; Tyler J; Casey H; Bosler D; Sobecks R; Hamilton B; Sauter C; Mineishi S; Claxton D; Shike H
J Mol Diagn; 2024 Apr; 26(4):233-244. PubMed ID: 38307253
[TBL] [Abstract][Full Text] [Related]
3. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
4. Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methods.
Brow D; Shike H; Kendrick J; Pettersson L; Mineishi S; Claxton DF; Wirk B; Cioccio J; Greiner RJ; Viswanatha D; Kharfan-Dabaja MA; Li Z; Tyler J; Elrefaei M
Hum Immunol; 2024 May; 85(3):110794. PubMed ID: 38553384
[TBL] [Abstract][Full Text] [Related]
5. Chimerism Testing by Next Generation Sequencing for Detection of Engraftment and Early Disease Relapse in Allogeneic Hematopoietic Cell Transplantation and an Overview of NGS Chimerism Studies.
Liacini A; Tripathi G; McCollick A; Gravante C; Abdelmessieh P; Shestovska Y; Mathew L; Geier S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511573
[TBL] [Abstract][Full Text] [Related]
6. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
7. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
8. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
[TBL] [Abstract][Full Text] [Related]
9. The mythological chimera and new era of relapse prediction post-transplant.
Ciurea SO; Kothari A; Sana S; Al Malki MM
Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
[TBL] [Abstract][Full Text] [Related]
10. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U; Haferlach T; Fehse B; Schnittger S; Kröger N
ScientificWorldJournal; 2011 Feb; 11():310-9. PubMed ID: 21298222
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong E; Mason K; Collins J; Hockridge B; Boyd J; Gorelik A; Szer J; Ritchie DS
Biol Blood Marrow Transplant; 2017 May; 23(5):840-844. PubMed ID: 28167152
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Monitoring of Mutation and Chimerism Using Next-Generation Sequencing in Myelodysplastic Syndrome.
Lee JM; Kim YJ; Park SS; Han E; Kim M; Kim Y
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31795155
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.
Bornhäuser M; Oelschlaegel U; Platzbecker U; Bug G; Lutterbeck K; Kiehl MG; Schetelig J; Kiani A; Illmer T; Schaich M; Theuser C; Mohr B; Brendel C; Fauser AA; Klein S; Martin H; Ehninger G; Thiede C
Haematologica; 2009 Nov; 94(11):1613-7. PubMed ID: 19880783
[TBL] [Abstract][Full Text] [Related]
20. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.
Stasik S; Burkhard-Meier C; Kramer M; Middeke JM; Oelschlaegel U; Sockel K; Ehninger G; Serve H; Müller-Tidow C; Baldus CD; Röllig C; Bornhäuser M; Platzbecker U; Thiede C
Blood Adv; 2022 Jun; 6(11):3294-3303. PubMed ID: 35320339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
